Similar articles

• Babesiosis in a patient on infliximab for Crohn's disease.

  Cullen G, Sands BE, Yajnik V. Cullen G, et al. Inflamm Bowel Dis. 2010 Aug;16(8):1269-70. doi: 10.1002/ibd.21158. Inflamm Bowel Dis. 2010. PMID: 19885904 No abstract available.
• Intense muscle aches after cleaning a boat on the Amsterdam canals.

  van Sandwijk MS, Boerrigter BG, van Veen SQ, van den Berk GE. van Sandwijk MS, et al. Neth J Med. 2013 Jul-Aug;71(6):316, 320. Neth J Med. 2013. PMID: 23956314 No abstract available.
• Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.

  Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP. Chaparro M, et al. J Clin Gastroenterol. 2011 Feb;45(2):113-8. doi: 10.1097/MCG.0b013e3181ebaef9. J Clin Gastroenterol. 2011. PMID: 21242747
• Infliximab treatment for Crohn's disease.

  Conroy CA, Cattell R. Conroy CA, et al. Postgrad Med J. 2001 Jul;77(909):436-40. doi: 10.1136/pmj.77.909.436. Postgrad Med J. 2001. PMID: 11423591 Free PMC article. Review. No abstract available.
• Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.

  Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G. Feagan BG, et al. Can J Clin Pharmacol. 2001 Winter;8(4):188-98. Can J Clin Pharmacol. 2001. PMID: 11743591 Review.